Novartis

OverviewSuggest Edit

Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2021)110,000(+4%)
Job Openings1,803
Revenue (FY, 2021)$52.9 B(+6%)
Share Price (May 2022)CHF87.4
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer
Joerg Reinhardt

Joerg Reinhardt

Chairman
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Klaus Moosmayer

Klaus Moosmayer

Chief Ethics, Risk & Compliance Officer
Richard Saynor

Richard Saynor

Chief Executive Officer of Sandoz
Shannon Thyme Klinger

Shannon Thyme Klinger

Chief Legal Officer
Show more

Novartis Office Locations

Novartis has offices in Basel, Pratteln, Rotkreuz ZG, Stein and in 167 other locations
Basel, CH (HQ)
Novartis Forum 1, Fabrikstrasse 6
Basel, CH
210, Lichtstrasse 35
Basel, CH
Fabrikstrasse 2
Pratteln, CH
Schweizerhalle, Rheinstrasse 52
Rotkreuz ZG, CH
Suurstoffi 14
Stein, CH
Schaffhauserstrasse
Show all (186)

Novartis Financials and Metrics

Novartis Revenue

Novartis's revenue was reported to be $52.88 b in FY, 2021
USD

Revenue (FY, 2021)

52.9b

Gross profit (FY, 2021)

45.1b

Net income (FY, 2021)

24.0b

EBITDA (FY, 2021)

33.2b

EBIT (FY, 2021)

27.0b

Market capitalization (17-May-2022)

193.4b

Closing stock price (17-May-2022)

87.4

Cash (31-Dec-2021)

12.4b

EV

212.0b
Novartis's current market capitalization is CHF193.4 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

53.2b50.5b49.9b52.9b

Cost of goods sold

(11.7b)(9.4b)(8.6b)(9.7b)

Gross profit

43.2b43.1b43.0b45.1b

R&D expense

(9.1b)(9.5b)(9.0b)(9.5b)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

11.2b14.1b12.5b12.3b12.0b12.5b12.4b13.6b13.4b

Cost of goods sold

(1.8b)(3.2b)(4.9b)(2.3b)(1.7b)(2.0b)(2.3b)(4.2b)(788.0m)

Gross profit

9.8b11.6b7.8b10.7b10.3b10.9b10.7b9.9b13.0b

R&D expense

(2.3b)(2.2b)(2.2b)(2.1b)(2.4b)(2.1b)(2.4b)(2.4b)(2.4b)
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

13.3b11.1b9.7b12.4b

Accounts Receivable

8.7b8.3b8.2b8.0b

Prepaid Expenses

1.1b1.2b1.2b1.4b

Inventories

7.0b6.0b7.1b6.7b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

6.8b10.0b8.4b4.5b5.9b9.0b3.8b5.1b7.2b

Accounts Receivable

7.6b8.0b7.8b8.5b7.6b8.1b8.3b8.4b8.4b

Prepaid Expenses

233.0m279.0m244.0m254.0m308.0m226.0m216.0m254.0m255.0m

Inventories

5.7b6.1b6.1b6.4b6.9b7.1b7.0b7.1b6.9b
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

12.6b7.1b8.1b24.0b

Depreciation and Amortization

6.9b5.5b6.1b5.8b

Inventories

(533.0m)(382.0m)(543.0m)81.0m

Accounts Payable

309.0m553.0m(324.0m)(21.0m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

1.9b4.0b6.0b2.2b4.0b6.0b2.1b2.9b7.7b

Depreciation and Amortization

1.4b2.5b3.9b1.3b3.0b4.6b1.6b1.4b4.4b
USDFY, 2018

Revenue/Employee

424.8k
Show all financial metrics

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Major Approvals (US, EU, JP)

20161615

Major Submissions (US, EU, JP)

1424162030

Patients Reached

972 m965 m927 m

Projects Entering Development Pipeline

859

Novartis Acquisitions / Subsidiaries

Company NameDateDeal Size
Gyroscope TherapeuticsDecember 22, 2021$1.5 b
Arctos MedicalSeptember 17, 2021
CellerysJune 01, 2021
Cadent TherapeuticsDecember 17, 2020$770 m
Vedere BioOctober 29, 2020$280 m
Vedere Bio llOctober 29, 2020$280 m
AmblyotechApril 21, 2020
The Medicines CompanyNovember 25, 2019$9.7 b
XiidraMay 09, 2019$1.9 b
Novartis Inflammasome ResearchApril 02, 2019$1.58 b
Show more

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 18.7% from SANDOZ, 83.2% from INNOVATIVE MEDICINES and -1.8% from Other

Human Capital Metrics

Embed Graph

Novartis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Novartis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Novartis Online and Social Media Presence

Embed Graph

Novartis Company Culture

  • Overall Culture

    A+

    78/100

  • CEO Rating

    A+

    88/100

  • Compensation

    A+

    90/100

  • Diversity

    A+

    83/100

Learn more on Comparably

Novartis News and Updates

Global Osteoarthritis (IA Injections, NSAIDs & Analgesics) Market Research Report 2022-2026 Featuring Johnson & Johnson, Novartis, Bayer, GlaxoSmithKline, Pfizer and Sanofi

DUBLIN, May 18, 2022 /PRNewswire/ -- The "Global Osteoarthritis Market (IA Injections, NSAIDs & Analgesics): Insights, Trends & Forecast (2022-2026)" report has been added to ResearchAndMarkets.com's offering. The global osteoarthritis market revenues are forecasted to touch US$12.14...

Novartis suspends delivery of cancer treatment as it address potential production issues

The U.S.-listed shares of Novartis AG fell 2.6% in afternoon trading Thursday, after the Switzerland-based drug maker said it was "temporarily" suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jers…

Global AI in Pharma Market Report (2022 to 2031) - Featuring Novartis, Merck and GNS Healthcare Among Others

Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "AI In Pharma Global Market Report 2022, By Technology, Drug Type, Application" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to asse…

Tact.ai Establishes Customer Advisory Board, Names Former Novartis Pharma Global CIO and SVP Andreas Müller as Advisor

SUNNYVALE, Calif., May 4, 2022 /PRNewswire/ -- Tact.ai, the customer engagement company for life sciences, announced today that former Novartis Pharma Global CIO and SVP, Andreas Müller, has joined the company as an Advisor. His role will focus on working with commercial and medical...

New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients

Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanc…

Global Gastro Esophageal Reflux Disease Drug Market to 2027 - Featuring GlaxoSmithKline, Medtronic and Novartis Among Others

Dublin, April 29, 2022 (GLOBE NEWSWIRE) -- The "Global Gastro Esophageal Reflux Disease (GERD) Drug Market 2021-2027" report has been added to ResearchAndMarkets.com's offering. The global Gastro Esophageal Reflux Disease (GERD) market is anticipated to grow at a considerable CAGR during the forec…
Show more

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Harry Kirsch.

  • How many employees does Novartis have?

    Novartis has 110,000 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $52.9 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $480.7 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Merck Group, Bausch + Lomb and Immunomedics.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Novartis Forum 1, Fabrikstrasse 6, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Pratteln, Rotkreuz ZG, Stein and in 167 other locations.

  • How many offices does Novartis have?

    Novartis has 186 offices.